Free Trial
OTCMKTS:MKGAF

Merck KGaA (MKGAF) Stock Price, News & Analysis

Merck KGaA logo
$131.25 +1.51 (+1.16%)
As of 06/30/2025 03:54 PM Eastern

About Merck KGaA Stock (OTCMKTS:MKGAF)

Key Stats

Today's Range
$129.00
$133.05
50-Day Range
$124.46
$143.90
52-Week Range
$118.05
$200.56
Volume
1,173 shs
Average Volume
1,102 shs
Market Capitalization
$16.96 billion
P/E Ratio
20.04
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Strong Buy

Company Overview

Merck KGaA, operating under the OTCMKTS:MKGAF ticker, is a leading science and technology company headquartered in Darmstadt, Germany. Founded in 1668, the firm remains majority-owned by the founding Merck family and has grown from a small pharmacy into a global enterprise. Its activities span three core business sectors—Healthcare, Life Science and Performance Materials—serving customers in pharmaceuticals, biotechnology, electronics and specialty chemicals.

In its Healthcare division, Merck KGaA develops and markets prescription medicines in areas such as oncology, immuno-inflammation and fertility. The company’s research and development focus includes targeted cancer therapies, emerging immunotherapies and innovative treatment options for women’s health. Clinical studies are conducted at multiple sites worldwide, reflecting Merck KGaA’s commitment to advancing patient care and expanding its therapeutic pipeline.

The Life Science segment provides tools, consumables and services for biopharmaceutical research, diagnostics and production. Offerings include laboratory reagents, single-use technologies and bioprocess solutions designed to accelerate drug development and manufacturing. In parallel, the Performance Materials arm delivers high-tech solutions for semiconductor manufacturing, consumer electronics and surface treatment, supplying specialty chemicals, liquid crystals for displays and ultraviolet curable resins.

With operations in over 60 countries and production facilities on four continents, Merck KGaA combines a global footprint with a decentralized management structure. Under the leadership of Chief Executive Officer Belén Garijo and an executive board drawn from diverse scientific and commercial backgrounds, the company emphasizes sustainable growth, strategic partnerships and digital transformation. Its broad geographic reach and diversified portfolio position Merck KGaA as a prominent player in multiple high-growth industries.

AI Generated. May Contain Errors.

Merck KGaA Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
27th Percentile Overall Score

MKGAF MarketRank™: 

Merck KGaA scored higher than 27% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Merck KGaA are expected to grow by 8.21% in the coming year, from $9.75 to $10.55 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Merck KGaA is 20.04, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.77.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Merck KGaA is 20.04, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.44.

  • Price to Book Value per Share Ratio

    Merck KGaA has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Merck KGaA's valuation and earnings.
  • Percentage of Shares Shorted

    0.46% of the float of Merck KGaA has been sold short.
  • Short Interest Ratio / Days to Cover

    Merck KGaA has a short interest ratio ("days to cover") of 99.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Merck KGaA has recently increased by 1.94%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Merck KGaA does not currently pay a dividend.

  • Dividend Growth

    Merck KGaA does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.46% of the float of Merck KGaA has been sold short.
  • Short Interest Ratio / Days to Cover

    Merck KGaA has a short interest ratio ("days to cover") of 99.8, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Merck KGaA has recently increased by 1.94%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Merck KGaA has a news sentiment score of 1.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Merck KGaA this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Merck KGaA insiders have not sold or bought any company stock.

  • Percentage Held by Institutions

    Only 0.10% of the stock of Merck KGaA is held by institutions.

  • Read more about Merck KGaA's insider trading history.
Receive MKGAF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck KGaA and its competitors with MarketBeat's FREE daily newsletter.

MKGAF Stock News Headlines

How to Collect Up To $5,917/mo From Trump’s Made In USA Boom
How to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First policies, a historic wave of investment is flooding back into the United States: Apple committing a colossal $500 billion to build new U.S. factories. Microsoft injecting $80 billion into domestic manufacturing. Nvidia moving critical chip production back to America. But here's the hidden opportunity: There's now a groundbreaking way for you to start collecting monthly checks from these very same companies— checks that could reach as high as $5,917 each month. Don't miss your chance to participate directly in America's industrial comeback.
See More Headlines

MKGAF Stock Analysis - Frequently Asked Questions

Merck KGaA's stock was trading at $151.56 at the start of the year. Since then, MKGAF shares have decreased by 13.4% and is now trading at $131.25.
View the best growth stocks for 2025 here
.

Shares of MKGAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
7/01/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:MKGAF
CIK
N/A
Employees
62,908
Year Founded
N/A

Profitability

Trailing P/E Ratio
20.04
Forward P/E Ratio
13.46
P/E Growth
N/A
Net Income
$3.06 billion
Pretax Margin
15.64%

Debt

Sales & Book Value

Annual Sales
$22.72 billion
Cash Flow
$39.53 per share
Price / Cash Flow
3.32
Book Value
$212.00 per share
Price / Book
0.62

Miscellaneous

Free Float
N/A
Market Cap
$16.96 billion
Optionable
Not Optionable
Beta
0.96

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (OTCMKTS:MKGAF) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners